PharmaLink Announces Execution Of Returns Processing Service Agreement With Merck

PharmaLink, Inc., an Industry-leading pharmaceutical reverse distributor, announced today a new contract relationship with biopharmaceutical manufacturer Merck Sharp & Dohme LLC (Merck). The new Returns Processing Service Agreement is expected to enhance the returns process for downstream customers while maintaining the integrity of supply chain security.

In tandem with this new contract, Merck will issue an updated Product Return Policy complete with directions to acquire a returned goods authorization on PharmaLink's web portal and new policy parameters. Returns processing activities will be assumed by PharmaLink beginning June 20, 2023.

Thierry Beckers, President & CEO of PharmaLink, noted, "We are excited to add Merck to our growing portfolio of top-tier biopharmaceutical clients. Sharing common values of integrity, innovation and customer focus makes for a collaborative partnership that will allow us to bring new value to our mutual customers."

For details on the transition of services to PharmaLink, please visit:

www.merckvaccines.com/wp-content/uploads/sites/8/2023/04/return-merchandise-letter.pdf

For more information, visit www.pharmalinkinc.com.